CN101623290A - Drospirenone analogue medicinal composition - Google Patents
Drospirenone analogue medicinal composition Download PDFInfo
- Publication number
- CN101623290A CN101623290A CN200810053770A CN200810053770A CN101623290A CN 101623290 A CN101623290 A CN 101623290A CN 200810053770 A CN200810053770 A CN 200810053770A CN 200810053770 A CN200810053770 A CN 200810053770A CN 101623290 A CN101623290 A CN 101623290A
- Authority
- CN
- China
- Prior art keywords
- daily dose
- chemical compound
- formula
- equivalent
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal composition taking a drospirenone analogue as an active ingredient, which consists of the compound shown as the formula (I) used as the first active ingredient, one or more synthetic estrogen used as a second active ingredient and one or more medicinal carriers or excipients, wherein the content of the compound shown as the formula (I) is equivalent to daily dose of 10 to 30mu g/kg; and the content of the synthetic estrogen is equivalent to daily dose of 0.2 to 1mu g/kg. The medicinal composition is used for preparing contraception medicaments of human or mammals.
Description
Technical field
The present invention relates to a kind of is the pharmaceutical composition that is used to prepare contraceptive of active component with the drospirenone analogue as progestogen.
Background technology
Drospirenone (Drospirenone, DRSP) be the derivant of a kind of 17 α-spironolactone, be a kind of synthetic progestogen, with progestational hormone seemingly, with progesterone receptor, mineralcorticoid receptor affinity is highly arranged, very low with androgen receptor and glucocorticoid receptor (GR) affinity, do not combine with estrogen receptor.It combines the pharmacological characteristics of progestogen, anti mineralocorticoid and androgen antagonist, and this makes the biochemistry of DRSP and pharmacological properties and natural progestogen quite similar, has the not available progesterone activity of other synthetic hormones.As the analog of spironolactone, the receptor of this medicine and mineralocorticoid has the affinity of height, thereby has the effect of anti mineralocorticoid, can alleviate progestogen and estrogenic side effect.Therefore drospirenone is used to prepare oral contraceptive and treatment climacteric syndrome, US and European country in calendar year 2001 ratified commodity Yasmin (excellent think of is bright) by name by 3mg DRSP and 30 μ g EE (ethinylestradiols, Ethinylestradiol) clinical practice of the low dose oral contraceptives of Gou Chenging, the European Union and the U.S. also have been distributed in and had ratified that German schringAG produces in 2003 and 2004, by 0.5mg DRSP and 1mg E2 (estradiol, estradiol) form the oral formulations that is used for the treatment of climacteric syndrome of commodity Angeiq by name.In order to reduce the side effect of progestogen, people attempt to reduce the dosage of progestogen always in application, yet, for in order to be effective, the content of progestogen can't further reduce, therefore more efficient, selectivity is better, the littler novel progestogen of side effect just become people's target, Chinese patent application CN200580048680.3 discloses the analog of a kind of drospirenone of chemical formula (I)---18-methyl-6 β, 7 β-15 β, 16 β-dimethylene-3-oxo-19-is nor--pregnant-4 alkene-21 of 17-, the 17-lactone:
This application also discloses a series of general formula compounds that comprise in formula (I) chemical compound and has had the gestagen receptor affinity higher than drospirenone, yet in this application, specifically do not provide the gestagen receptor affinity data that formula (I) chemical compound is compared with drospirenone, and only having provided the daily dose of general formula compound in the contraception medicament in this application is 0.01-5mg, from prior art, learn, too high or too low progestogen consumption all can not be realized contraceptive effect well, and too high progestogen consumption also can bring pronounced side effects, and we can't learn that formula (I) can realize the concrete dosage in effective medicament of practising contraception from prior art.
Summary of the invention
In order to overcome defective of the prior art, in the research to formula (I) chemical compound, we have unexpectedly found the optimal daily dose as people or primates contraception medicament of this chemical compound.
We provide a kind of is the pharmaceutical composition of active component with formula (I) chemical compound, said composition is by constituting as formula (I) chemical compound of first kind of active component with as one or more synthetic estrogen and one or more pharmaceutically useful carriers or excipient of second kind of active component, the content of its Chinese style (I) chemical compound is equivalent to the daily dose of 10 μ g/kg～30 μ g/kg, and the content of synthetic estrogen is equivalent to the daily dose of 0.2 μ g/kg～1 μ g/kg.
Pharmaceutical composition preferred formula of the present invention (I) compounds content is equivalent to the daily dose of 20 μ g/kg～30 μ g/kg.
Pharmaceutical composition of the present invention also preferably is equivalent to the daily dose of 0.4 μ g/kg～0.8 μ g/kg as second kind of active component for the content of synthetic estrogen.
The content of the also preferred described formula of Pharmaceutical composition of the present invention (I) chemical compound is equivalent to the daily dose of 20 μ g/kg, and the content of described synthetic estrogen is equivalent to the daily dose of 0.6 μ g/kg.
The content of the also preferred described formula of Pharmaceutical composition of the present invention (I) chemical compound is equivalent to the daily dose of 30 μ g/kg, and the content of described synthetic estrogen is equivalent to the daily dose of 0.6 μ g/kg.
Pharmaceutical composition of the present invention is the application in preparation human contraceptive preferably, and body weight for humans is in 50kg when calculating dosage.
In the Pharmaceutical composition of the present invention, as preferred synthetic estrogen, as in 17 α-ethinylestradiol (ethinylestradiol), the mestranol (mestranol) one or more, preferred ethinylestradiol.
Before pharmaceutical composition of the present invention can also be used to prepare treatment menopause, the medicine of menopause and PMS, and the medicine that is used to prepare hormone replacement therapy (HRT).
Formula in the pharmaceutical composition of the present invention (I) chemical compound and/or ethinylestradiol preferably adopt micronized form to provide, and described micronization is meant mean diameter D
50(meso-position radius, rate all just was the particle size values of 50% place correspondence under promptly sieve was gone up rate and sieved)≤5 μ m, special, D
90(sieve is rate 90% corresponding particle diameter down)≤10 μ m, the medicine of described micronization form helps formula (I) chemical compound and can dissolve in vivo rapidly when oral, improves the oral administration biaavailability of described formula (I) chemical compound.Can also adopt to be dissolved in organic solvent and to spray to method on the blank micropill core then, described method of micronization can adopt known breaking method, pulverizes as fluid energy mill.
Pharmaceutical composition of the present invention can be prepared according to method known to those skilled in the art, be about to formula (I) chemical compound, prepare, and make the peroral dosage form that needs as the synthetic estrogen of second kind of active component and pharmaceutically useful carrier or excipient.
Described dosage form includes but are not limited to tablet, coated tablet, capsule, pill, granule or suspensoid, implants, cutaneous permeable agent; The preferred oral preparation includes but are not limited to tablet, pill, coated tablet, granule, capsule, suspensoid.Special preferred tablet, capsule, granule.
Comprise in the pharmaceutical composition of the present invention that pharmaceutically useful carrier that known oral formulations is used or excipient are to include but are not limited in filler, wetting agent and binding agent, disintegrating agent, lubricant, coloring agent, the correctives one or more,
Described pharmaceutically useful carrier or excipient can be selected from but be not limited only in the following material one or more:
Starch includes but are not limited to corn starch, wheaten starch, potato starch; Saccharide, preferred sucrose, glucose, the lactose of pulverizing; Sugar alcohols, preferred mannitol, sorbitol, xylitol; Dextrin, preferred beta-schardinger dextrin-; Cellulose derivative comprises methylcellulose (MC), hydroxypropyl cellulose (HPC), hydroxypropyl emthylcellulose (HPMC), sodium carboxymethyl cellulose (CMC-Na), ethyl cellulose (EC); And gelatin, polyvinylpyrrolidone (PVP), Polyethylene Glycol (PEG, PEG4000 commonly used or PEG6000), carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), cross-linking sodium carboxymethyl cellulose (CCNa), crospolyvinylpyrrolidone (PVPP), magnesium stearate, micropowder silica gel, Pulvis Talci, purified water, ethanol, microcrystalline Cellulose, pregelatinized Starch.
Especially, pharmaceutical composition of the present invention can also be made enteric coated tablet, enteric coated capsule with the method for conventional enteric coated preparation.As adopt credulity to restrain
TM(EASCOL
TM, Tianjin Aileyi Medicine Materials Co., Ltd. produces) and serial enteric coating agents carries out coating, makes enteric coated tablet or enteric coated particles, enteric coated capsule etc.Also can make the general thin garment piece (the HPMC coating, as, easily release beautiful
TM, Tianjin Aileyi Medicine Materials Co., Ltd. produces), conventional capsule, plain particles agent.
Pharmaceutical composition of the present invention can provide in order to following method: micronized formula (I) chemical compound that will make fully mixes with the pharmaceutically acceptable auxiliaries as carrier or excipient, add dissolving or pulverize binding agent in solvent or dispersant, carry out pelletize, then with the granule tabletting, optionally can add proper amount of lubricating agent or fluidizer, also granule can be irritated capsule and make capsule
Pharmaceutical composition of the present invention also can provide in order to following method: micronized formula (I) chemical compound that will make fully mixes with the pharmaceutically acceptable auxiliaries as carrier or excipient, then powder is directly carried out direct compression.Also can well-mixed pastille powder directly pour into capsule and make capsule, the tablet of gained or capsule also all can carry out coating.
Pharmaceutical composition of the present invention can also provide in order to following method: be dissolved in the suitable organic solvent with formula (I) chemical compound and/or as the synthetic estrogen of second kind of medicinal ingredient, as methanol, ethyl acetate, in the ethanol etc. one or more, and it is sprayed onto on blank micropill nuclear core or the coated tablet label, obtain pastille micropill or pastille label, described celphere can be preferably from the sucrose ball core of the commercially available definition that meets American Pharmacopeia 25 editions, microcrystalline Cellulose ball core, a kind of in the starch ball core, the diameter of described celphere is 0.1mm～1mm.Adopt the method for fluidized bed coating or pan coating, preferably pastille label or pastille micropill are carried out coating with above-mentioned enteric coating agents, obtain enteric coated micropill or enteric coatel tablets, enteric coated micropill is poured into capsule promptly get capsule, described coating method is with reference to (developments of verapamil hydrochloride pulse controlled release micro pill such as Zhang Yu, Chinese Journal of Pharmaceuticals, 2003.34 (5), 236～237) the virtuous grade of the He Lianggui (development of diltiazem hydrochloride colon patch, Chinese Journal of Pharmaceuticals, 2003.34 (5), 233～235) disclosed method.
Can also with the coating that makes or not the pastille micropill of coating add an amount of disintegrating agent such as in the microcrystalline Cellulose one or more, filler such as starch, sugar, dextrin, in one or more, pregelatinized Starch, binding agent such as polyvinylpyrrolidone (PVP), cellulose derivative is as comprising methylcellulose (MC), hydroxypropyl cellulose (HPC), hydroxypropyl emthylcellulose (HPMC), sodium carboxymethyl cellulose (CMC-Na), ethyl cellulose (EC), Macrogol 4000 (PEG4000), polyethylene glycol 6000 (PEG6000), disintegrating agent carboxymethyl base Starch Sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), cross-linking sodium carboxymethyl cellulose (CCNa), in the crospolyvinylpyrrolidone (PVPP) one or more, lubricant such as magnesium stearate.Adopt known compressing dry granulation or wet method tabletting method to make tablet, and preferably the tablet that makes is carried out coating, described coating can be an enteric coating, also can be the coating of common cellulose derivative film.
This pastille micropill of not coating directly can also be poured in the capsule and to capsule and carry out coating, described coating can be an enteric coating, also can be the coating of common cellulose derivative film.
Described pastille micropill is at coating or all can not be prepared under the situation of coating and be used for directly oral granule.
Described pharmaceutical composition can also adopt with micronized formula as first kind of active component (I) chemical compound with as one or more of the synthetic estrogen of second kind of active component and replace above-mentioned pastille micropill, directly make tablet, capsule, made capsule and tablet preferably carry out coating, described coating can be an enteric coating, also can be the coating of common cellulose derivative film.
The oral formulations that described pharmaceutical composition is made, wherein enteric coated preparation meets 2005 editions appendix XD of Chinese Pharmacopoeia drug release determination method, 2 hours release≤5% in the hydrochloric acid solution of pH=1,45 minutes release 〉=70% in the phosphate buffer of pH=6.8, non-enteric coated preparation meets 2005 editions appendix XC of Chinese Pharmacopoeia dissolution method, 45 minutes dissolution 〉=70% in the hydrochloric acid solution of pH=1.
The content that this drug oral compositions can be made described formula (I) chemical compound is equivalent to daily dose (0.5～1.5mg/d of 10 μ g/kg～30 μ g/kg, people's body weight is in 50kg), the content of synthetic estrogen is equivalent to the oral formulations of the daily dose of 0.2 μ g/kg～1 μ g/kg.(0.01～0.05mg/d, people's body weight is in 50kg)
The content of preferably making formula (I) chemical compound is equivalent to the pharmaceutical preparation of the daily dose of 20 μ g/kg～30 μ g/kg (1.0～1.5mg/d, people's body weight is in 50kg)
Also preferably be made as second kind of active component for synthetic estrogen be the pharmaceutical preparation that content is equivalent to the daily dose of 0.4 μ g/kg～0.8 μ g/kg.(0.02～0.04mg/d, people's body weight is in 50kg).
More preferably make the oral formulations that the synthetic estrogen of 1 to 1.5mg formula (I) chemical compound and 0.02～0.04mg is contained in each daily dose unit, the preferred ethinylestradiol of described synthetic estrogen.
Above-mentioned oral formulations, preferably formula (I) chemical compound of 1mg and the synthetic estrogen of 0.03mg, the preferred ethinylestradiol of described synthetic estrogen are contained in each daily dose unit.
Above-mentioned oral formulations, preferably formula (I) chemical compound of 1.5mg and the synthetic estrogen of 0.03mg, the preferred ethinylestradiol of described synthetic estrogen are contained in each daily dose unit.
According to known human contraceptive using method (body weight for humans is in 50kg), Pharmaceutical composition of the present invention can also make by the cycle administration by at least 21 contain described two kinds of active component and 7 or the single preparation that does not contain formula (I) chemical compound (tablet, capsule, pill) still less single phase preparation or in the administration cycle by contain the different activities component content the multistage preparation that constitutes of single preparation (tablet, capsule, pill).Thus, pharmaceutical composition of the present invention can be made the pharmaceutical preparation of being made up of a plurality of independent packagings and the daily dose unit that can take out separately, described daily dose unit places in the packaging unit, be used for oral administration in the continuous at least 21 days time, formula (I) chemical compound of 0.5～1.5mg and the synthetic estrogen of 0.01～0.05mg are contained in wherein said each daily dose unit, formula (I) chemical compound of 1～1.5mg and the synthetic estrogen of 0.02～0.04mg are contained in preferred each daily dose unit, the preferred ethinylestradiol of described synthetic estrogen also can be a mestranol.
As improvement to above-mentioned preparation, Pharmaceutical composition of the present invention also can make by the cycle administration by at least 21 contain described two kinds of active component and 7 or the single preparation that only contains synthetic estrogen (tablet, capsule, pill) still less single phase preparation or in the administration cycle by the multistage preparation of the single preparation that contains the different activities composition (tablet, capsule, pill).Thus, pharmaceutical composition of the present invention can be made the pharmaceutical preparation of being made up of a plurality of independent packagings and the daily dose unit that can take out separately, described daily dose unit places in the packaging unit, formula (I) chemical compound of 0.5～1.5mg and the synthetic estrogen of 0.01～0.05mg are contained in described each each daily dose unit of wherein containing two kinds of active component, preferably contain formula (I) chemical compound of 1.0～1.5mg and the synthetic estrogen of 0.02～0.04mg; The described daily dose unit of only containing synthetic estrogen, it contains the synthetic estrogen of 0.01～0.05mg, preferably contains 0.02～0.04mg synthetic estrogen, and the preferred ethinylestradiol of described synthetic estrogen also can be a mestranol.
Single phase that described Pharmaceutical composition is made or multistage preparation, containing active component daily dose unit can be 21～24, and the single preparation that does not contain formula (I) chemical compound as active component is 4～7, and each administration cycle is at least 28 days, the described multistage can be 2～4 stages.
Compositions of the present invention can also be the form of parenteral formulation, for example subcutaneous implant or percutaneous preparation, in order to prepare implant, active component can be used for example polysiloxane polymer, ethylene vinyl acetate, polyethylene or polypropylene preparation of one or more conjugates of corruption or degraded gradually in use.
When relating to percutaneous preparation, percutaneous preparation can be made the form of skeleton, film or the liquid in oil or hydrogel or thickness preparation.For the percutaneous patch; should comprise can with the binding agent of skin-compatible for example polyacrylate, polyorganosiloxane adhesive or polyisobutylene, and the lining of making by for example polyethylene, polypropylene, ethylene vinyl acetate, polrvinyl chloride, polyvinylidene chloride or polyester and by for example polyester or be coated with polysiloxane or the protection that can remove lining that fluoropolymer polymer is made.When preparation percutaneous solution or gel, can make water or organic solvent or its mixture.The percutaneous gel can also contain one or more suitable gellant or thickening agent for example polysiloxanes, tragcanth, starch or starch derivatives, cellulose or cellulose derivative or polyacrylic acid or derivatives thereof.Percutaneous preparation can also suitably contain one or more can promote material by skin absorbs, for example bile salt or derivatives thereof and/or phospholipid.Suitable percutaneous preparation can according to WO94/04157 in the similar mode of the method for preparing the 3-keto-desogestrel percutaneous preparation described prepare.Perhaps, percutaneous preparation can be according to for example BWBarry; " Dermatological Formulations, Percutaneous Absorption ", Marcel Dekker Inc.; NewYork-Basel; 1983 or YW Chien, " Transdermal Controlled Systemic Medications ", Marcel DekkerInc.; NewYork-Basel, disclosed method preparation in 1987.
The specific embodiment
The following specific embodiment is in order better to explain and to understand technical scheme of the present invention, can not be interpreted as by any way the qualification to the claimed technical scheme of the present invention.
Example of formulations
Embodiment 1
The label that has following composition by following method preparation: (label is 100mg)
Micronized formula (I) chemical compound 1.00mg
Micronized ethinylestradiol 0.03mg
Lactose monohydrate 61.40mg
Corn starch 19.10mg
Pregelatinized Starch starch 1500 12.9mg
Polyvinylpyrrolidone K25 (mean molecule quantity 30000) 500mg
Magnesium stearate 0.57mg
Feed intake to prepare 10000; to add fluidized bed pelletizer except that the above-mentioned mixing of materials of the recipe quantity polyvinylpyrrolidone, the magnesium stearate; start fluid bed; the polyvinylpyrrolidone of recipe quantity is made into the spraying and carry out drying and granulating by the mode of heated fluidized bed continuously on fluid bed of 20% aqueous solution; magnesium stearate with recipe quantity when granulating end sucks fluidized bed pelletizer and abundant the mixing, the granule that obtains is carried out tabletting obtain label.Adopt commercially available HPMC coating materials (easily to release beautiful
TM, Tianjin Aileyi Medicine Materials Co., Ltd. produces) carry out coating and obtain desired Film coated tablets.The coating materials consumption is by heavy 6% the feeding intake of sheet, and every contains formula (I) chemical compound 1.00mg, ethinylestradiol 0.03mg.
Embodiment 1-1
Obtain label among the embodiment 1, adopt commercially available enteric coating agents (trade name: credulity gram
TM(EASC0L
TM, Tianjin Aileyi Medicine Materials Co., Ltd. produces) carry out coating and obtain enteric coated tablet, the coating materials consumption is by heavy 6% the feeding intake of sheet.Every contains formula (I) chemical compound 1.00mg, ethinylestradiol 0.03mg.
Embodiment 1-2
With the granule that obtains among the embodiment 1, adopt No. 4 capsules to irritate capsule and obtain 10000 of capsules.Every contains formula (I) chemical compound 1.00mg, ethinylestradiol 0.03mg.
Embodiment 1-3
The capsule that embodiment 1-2 is obtained adopts the coating materials of implementing among the 1-1 to carry out coating, obtains 10000 of enteric coated capsules.Every contains formula (I) chemical compound 1.00mg, ethinylestradiol 0.03mg.
Embodiment 2 (every or every capsule)
Micronization formula (I) chemical compound 1.5mg
Micronization ethinylestradiol 0.02mg
60～80 commercially available purpose celphere (as the XYT-MCC60/80 type microcrystalline Cellulose ball core of the special Science and Technology Ltd. in Xinyi, Shenzhen production) 15.0mg
Pregelatinized Starch starch 1500 15.2mg
Lactose monohydrate 4.5mg
Magnesium stearate 0.28mg
Feed intake according to 10000 of preparations, formula (I) chemical compound of recipe quantity and ethinylestradiol are dissolved in obtain medicinal liquid in the ethanol, the celphere of recipe quantity is added the coating machine, medicine liquid spray is made the pastille micropill on celphere.
With the adjuvant mixing direct compression of pastille micropill, and adopt the method for embodiment 1 that it is wrapped film-coat with other recipe quantities.Make Film coated tablets.Every contains formula (I) chemical compound 1.5mg, ethinylestradiol 0.03mg.
Embodiment 2-1
The label that embodiment 2 is made carries out coating by the enteric coating agents that adopts embodiment 1-1 and makes 10000 of enteric coated tablet.Every contains formula (I) chemical compound 1.5mg, ethinylestradiol 0.03mg.
Embodiment 2-2
With the pastille micropill that embodiment 2-2 makes, adopt No. 4 capsules to irritate capsule and obtain 10000 of capsules.Every contains formula (I) chemical compound 1.5mg, ethinylestradiol 0.03mg.
Embodiment 2-3
The capsule that embodiment 2-2 is made adopts the coating materials among the embodiment 1-1 to carry out coating, obtains 10000 every of enteric coated capsule and contains formula (I) chemical compound 1.5mg, ethinylestradiol 0.03mg.
Embodiment 3
Coating materials among the pastille micropill employing embodiment 1-1 that makes among the embodiment 2 is carried out coating obtain enteric coated micropill, enteric coated micropill is carried out tabletting according to the prescription of other adjuvants among the embodiment 2, obtain 10000 of sheets, every contains formula (I) chemical compound 1.5mg, ethinylestradiol 0.03mg.
Embodiment 3-1
Every content of dispersion is by the prescription of implementing 2, and the enteric coated micropill that embodiment 3 is made pours into capsule and obtains 10000 of capsules.Every contains formula (I) chemical compound 1.5mg, ethinylestradiol 0.03mg.
Embodiment 4
The stripping of effective ingredient and release
With embodiment 1-1, embodiment 1-3, embodiment 2-1, embodiment 2-3, embodiment 3, the enteric coated preparation that embodiment 3-1 makes is respectively got 6 (grains), measure formula (I) chemical compound release according to the assay method of the second method method 1 in 2005 editions appendix XD of Chinese Pharmacopoeia drug release determination respectively, with embodiment 1,1-2,2, the non-enteric coated preparation that 2-2 makes is respectively got 6 (grains) and is measured formula (I) chemical compound dissolution according to the assay method of first method in 2005 editions appendix XC of Chinese Pharmacopoeia dissolution method, all enteric coated preparation are 2 hours release≤5% in the hydrochloric acid solution of pH=1,45 minutes release 〉=70% in the phosphate buffer of pH=6.8, all non-enteric coated preparation are 45 minutes dissolution 〉=70% in the hydrochloric acid solution of pH=1, meet the regulation of appendix XD and appendix XC in the Chinese Pharmacopoeia 2005 editions respectively.
The same method is surveyed the dissolution of ethinylestradiol, also meets the regulation of appendix XD and appendix XC in the Chinese Pharmacopoeia 2005 editions respectively
Embodiment 5
The bioavailability of animal
Laboratory animal: 60 of female Beagle dogs, body weight (12.0 ± 0.5) kg, be divided into 12 groups, two matched groups, 10 experimental grouies, every group 5, fasting is 12 hours before the experiment, freely drink water, matched group adopts micronized effective ingredient suspension directly to irritate the method for stomach, matched group 1,2 adopt embodiment 1 respectively, the amount of the active component of 2 every (grain) is carried out administration, and experimental group adopts the preparation that makes among the embodiment to carry out gastric infusion, detects formula (I) the chemical compound relative bioavailability of comparing with matched group, group sees the following form with different embodiment and relativeness:
As seen from the above table, the preparation among the embodiment is directly irritated stomach with micronized formula (I) chemical compound and is compared, and relative bioavailability is about 100%, so the dosage form among the embodiment is suitable to pharmaceutical composition of the present invention.
Embodiment 6
Primate pharmacological evaluation (contraceptive effect)
The contrast medicine,
(1) adopt micronized drospirenone replace in embodiment 2 prescriptions formula (I) chemical compound, make enteric coating pastille micropill by the method among the embodiment 3, make pastille micropill that the blank micropill of every 15mg makes and contain the pastille micropill that the blank micropill of 3mg drospirenone, 0.03mg ethinylestradiol and every 15mg makes and contain 2mg drospirenone, two kinds of specifications of 0.03mg ethinylestradiol.Organize 1-1 in contrast, matched group 1-2 medication.
(2) the blank micropill that adopts embodiment 3 to adopt is produced enteric coating pastille micropill, organizes 2 medications (blank) in contrast
(3), produce every 15mg celphere respectively and contain according to the method for embodiment 3:
Experimental group 1:0.5mg formula (I) chemical compound 0.03mg ethinylestradiol
Experimental group 2:0.7mg formula (I) chemical compound 0.03mg ethinylestradiol
Experimental group 3:1.0mg formula (I) chemical compound 0.03mg ethinylestradiol
Experimental group 4:1.5mg formula (I) chemical compound 0.03mg ethinylestradiol
Experimental group 5:2.0mg formula (I) chemical compound 0.03mg ethinylestradiol
5 groups of enteric coating pastille micropills, respectively as the medication of experimental group 1～5.Successive administration 90d.
Laboratory animal: adopt healthy mature, 160 of the female macaques of normal menstrual cycle are arranged, 5～12 years old age of monkey, body weight 5.0 ± 0.5kg.Be divided into matched group 1-1, matched group 1-2 at random, matched group 2 and experimental group 1～5, are raised 2 months in advance to determine the menstrual cycle of monkey by 20 every group before the experiment.
Experimental technique: oral medicine-containing particle different grouping and the administration situation of feeding sees the following form:
Data are found out in the estrogen dosage and are under the situation of 0.06 μ g/kg from table, contain all ovulations of energy obvious suppression macaque of 0.01～0.03mg/kg formula (I) chemical compound, reach the effect of contraception, compare the inhibition ovulation rate with 0.04～0.06mg/kg drospirenone suitable substantially, formula (I) chemical compound that 0.01～0.03mg/kg is described thus can be realized identical contraceptive effect with ethinylestradiol compound recipe of forming and the compound recipe that 0.06mg/kg drospirenone and ethinylestradiol are formed, and as the average irregular bleeding number of times of side effect, experimental group 1～4 has no significant change, compare with experimental group 1, the average times of bleeding of experimental group 2～4 does not all have significance (P＞0.05), compare with experimental group 5, the average times of bleeding of experimental group 1～4 all has significance (P＜0.05), and from experimental data as can be seen the times of bleeding of experimental group 4 apparent in view increase has appearred, therefore can think that the dosage of working as formula (I) chemical compound is 0.01～0.03mg/kg, particularly during 0.02～0.03mg/kg, can either effectively realize contraception, can be good at controlling the side effect of irregular bleeding again, and obviously increase greater than the side effect of the irregular bleeding of 0.03mg/kg.
Embodiment 7
Animal pharmacology experiment (weight increase experiment
Laboratory animal: 160 of female 2 monthly age SD rats, body weight 200 ± 10g is divided into 8 groups, and 20 every group,
Experimental technique: carry out administration according to the following table grouping with the administration situation, guarantee the food ration and the quantity of motion basically identical of every experimental rat simultaneously, successive administration is surveyed the body weight of rat after 3 months
From experimental data as can be seen, administration through the long period, under the identical situation of ethinylestradiol dosage, 0.01 the formula of～0.03mg/kg (I) compound administration dosage does not have obvious influence to the average body weight average of rat, and compare with matched group 2, the average weight of experimental group 5 has significance (P＜0.05), similarly, we have observed when formula (I) compound administration dosage is 0.03mg/kg, and the trend that increases has appearred in the variation of rat average weight.Can draw 0.03mg/kg formula (I) compound administration dosage thus is the critical point that the weight increase side effect takes place, and formula (I) the compound administration dosage that can draw 0.01～0.03mg/kg thus is the dosage that can control side effect when effectively practising contraception that suits.
Claims (10)
1. a formula (I) chemical compound is the pharmaceutical composition of active component, by constituting as formula (I) chemical compound of first kind of active component with as one or more synthetic estrogens of second kind of active component and one or more pharmaceutically useful carriers or excipient, the content of described formula (I) chemical compound is equivalent to the daily dose of 10 μ g/kg～30 μ g/kg, and the content of described synthetic estrogen is equivalent to the daily dose of 0.2 μ g/kg～1 μ g/kg.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that the content of preferred described formula (I) chemical compound is equivalent to the daily dose of 20 μ g/kg～30 μ g/kg, preferred preferred ethinylestradiol of synthetic estrogen or mestranol, content is equivalent to the daily dose of 0.4 μ g/kg～0.8 μ g/kg.
3. pharmaceutical composition as claimed in claim 2 is characterized in that the content of preferred described formula (I) chemical compound is equivalent to the daily dose of 20 μ g/kg, and the content of described synthetic estrogen is equivalent to the daily dose of 0.6 μ g/kg.
4. pharmaceutical composition as claimed in claim 2 is characterized in that the content of preferred described formula (I) chemical compound is equivalent to the daily dose of 30 μ g/kg, and the content of described synthetic estrogen is equivalent to the daily dose of 0.6 μ g/kg.
5. as arbitrary described pharmaceutical composition in the claim 1 to 4, it is characterized in that the preferred ethinylestradiol of described synthetic estrogen.
6. as arbitrary described pharmaceutical composition in the claim 1 to 5, it is characterized in that described formula (I) chemical compound and/or synthetic estrogen preferably adopt micronization or be dissolved in organic solvent sprays to method administration on the blank micropill core then, and described micronization is meant mean diameter D
50≤ 5 μ m.
7. as arbitrary described pharmaceutical composition in the claim 1 to 6, it is characterized in that described pharmaceutical composition can make tablet, coated tablet, capsule, pill, granule, suspensoid, implants, cutaneous permeable agent.
8. pharmaceutical composition preferred oral preparation as claimed in claim 7, the content of described oral formulations Chinese style (I) chemical compound is equivalent to the daily dose of 10 μ g/kg～30 μ g/kg, the content of synthetic estrogen is equivalent to the daily dose of 0.2 μ g/kg～1 μ g/kg, the preferred ethinylestradiol of described synthetic estrogen.
9. the oral formulations that pharmaceutical composition as claimed in claim 8 is made, wherein the content of preferred formula (I) chemical compound is equivalent to the daily dose of 20 μ g/kg～30 μ g/kg, and the content of synthetic estrogen is equivalent to the daily dose of 0.4 μ g/kg～0.8 μ g/kg.
10 oral formulations as claimed in claim 9 is characterized in that preferably formula (I) chemical compound of 1.0～1.5mg and the synthetic estrogen of 0.02～0.04mg, the preferred ethinylestradiol of described synthetic estrogen are contained in each daily dose unit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810053770A CN101623290A (en) | 2008-07-07 | 2008-07-07 | Drospirenone analogue medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810053770A CN101623290A (en) | 2008-07-07 | 2008-07-07 | Drospirenone analogue medicinal composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101623290A true CN101623290A (en) | 2010-01-13 |
Family
ID=41519385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810053770A Pending CN101623290A (en) | 2008-07-07 | 2008-07-07 | Drospirenone analogue medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101623290A (en) |
-
2008
- 2008-07-07 CN CN200810053770A patent/CN101623290A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100857344B1 (en) | Pharmaceutical combination of ethynylestradiol and drospirenone for use as contraceptive | |
| EP1611892B1 (en) | Pharmaceutical compositions comprising drospirenone | |
| EP1670440B1 (en) | Hrt formulations | |
| US6787531B1 (en) | Pharmaceutical composition for use as a contraceptive | |
| PL198425B1 (en) | Micronized eplerenone compositions | |
| JP2011500793A (en) | Combination of antiemetics and oral contraceptives | |
| EP2409690A2 (en) | Improved stability of progestogen formulations | |
| CN101990427A (en) | Combination of mitiglinide and metformin and process for preparing same | |
| RU2449796C2 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone uses as contraceptive | |
| CN109646417B (en) | Trimetazidine sustained release tablet and preparation method thereof | |
| CN101623289A (en) | Novel drospirenone analogue medicinal composition | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| CN101623290A (en) | Drospirenone analogue medicinal composition | |
| CN101623287B (en) | Novel drospirenone analogue medicinal composition for treating menopausal syndrome | |
| WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
| CN101623288A (en) | Medicinal composition containing drospirenone analogue for treating menopausal syndrome | |
| EP2305267A2 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| AU2014227490A1 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| CN103610660B (en) | As the enteric coated tablet of hormonal medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100113 |